Biostem Technologies New

Good day, everyone, and welcome to the BioSTEM Technologies fourth quarter and full year 2024 conference call. Just a reminder that today's call is being recorded. At this time, I would like to hand things over to Mr. Adam Holdsworth. Please go ahead.

Good afternoon, everyone, and thank you for joining our conference call to discuss BioSTEM's fourth quarter full year 2024 financial results and corporate highlights. Leading the call today will be Jason Monashevsky, the company's founder and chief executive officer, and Mike Fortunato, the company's chief financial officer. Before we begin, I'd like to remind everyone that our remarks today may contain forward-looking statements based on the current expectations of management, which involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated. These risks are described in the company's filings with the over-the-counter market. You are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date made and may change at any time. While we may update or revise these statements from time to time, the company undertakes no commitment to do so unless required by political securities laws. This call also includes references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available in the company's earnings press release on the investor relations section of BioSend's website. With that, I'm now pleased to turn the call over to Jason Monashevsky. Jason?

Thank you, Adam, and thank you all for joining us today. Before we begin today's call, I want to turn the call over to Mike to address the delay in our Form 10 and the challenges we've encountered related to revenue and recognition under ASC 606. We believe that these are the remaining issues associated with allowing our Form 10 to become effective.